AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03888235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate corrective exercises
Description: The sacroiliac forward flexion test (SIFFT) finds the position of each innominate bone. Subjects learn 1 of 3 exercises. To correct anterior rotation, flex the thigh hard against the ilium, pushing it backwards. To correct posterior rotation, hyperextend the thigh to pull the ilium forward. 1.Genuflect, anterior foot and posterior knee on the floor hands on the floor on either side of the foot, sliding the knee backwards to hyperextend the thigh. 2. Supine, anterior foot on an assistant's sternum, posterior thigh hyperextended. Assistant leans forward, forcing the anterior thigh against the ilium and pushing down on the posterior thigh. 3. For anterior rotation alone: anterior foot on a chair seat, pulling up hard with both hands, leaning back, forcing the thigh against the ilium. Hold position for 2 minutes. Use as needed for pain control. They are reassessed one month later when they receive the pelvic support belt. Both treatments used together will be assessed one month after.
Study NCT03888235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate use of pelvic support belt
Description: Participants will be given a pelvic support belt to stabilize their sacroiliac joints. The belt is fitted tightly around the pelvis, over the sacrum and below the anterior superior iliac spines (ASISs) to prevent opening the joint. (The upper part of the innominate bones flares out so pushing them inwards will move the lower part outwards, away from the sacrum, opening the sacroiliac joints, increasing their instability). They will use this belt for activities which have in the past precipitated back pain. They will be reassessed one month later.~At that time they will be given the exercises to correct their sacroiliac malrotation and the concurrent use of both treatments will be assessed at their last visit one month later.
Study NCT03888235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed treatment
Description: Participants will continue the treatments they are currently using to relieve their low back pain for one month. At their one-month visit, they will be taught how to assess the direction of sacroiliac malrotation and how to do the corrective exercise. They will also be fitted for a pelvic stabilization belt.
Study NCT01476904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mcg/inhalation, 2 inhalations QID
Study NCT01476904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primatene Mist
Description: 220 mcg/inhalation, 2 inhalations QID
Study NCT01476904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine inhalation
Description: 125 mcg/inhalation, 2 inhalations QID
Study NCT00870324 — intervention group
Intervention type: DEVICE
Intervention: Tendril Lead
Description: The Tendril® is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in either the atrium or the ventricle. The tip-to-ring spacing in the Tendril is wide spaced compared to the OptiSense lead.
Study NCT03734458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A - PRF plus AFG with a CAF
Description: Group A - PRF plus AFG with a CAF will be used surgically to cover the exposed roots.
Study NCT03734458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B - PRF only with a CAF
Description: Group B - PRF only with a CAF will be used surgically to cover the exposed roots.
Study NCT03734458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group C - CTG with a CAF
Description: Group C - CTG with a CAF will be used surgically to cover the exposed roots.
Study NCT01354301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: intravenously, beginning within the first 24 hours after graft revascularization. Pre-treatment includes hydrocortisone and dipyrone before antithymocyte globulin infusion, which will be reconstituted according to the package insert.
Study NCT01354301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.
Study NCT01354301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximabe
Description: days 0 and 4, according to the package insert instructions.
Study NCT01354301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximabe
Description: days 0 and 4, according to the package insert instructions.
Study NCT01354301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate sodium
Description: 720 mg BID. This dose will be reduced according to adverse events.
Study NCT01354301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.05 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-5 ng/ml.
Study NCT01354301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml and 3-5 ng/ml after 3 months.
Study NCT00920829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone 50 Mg
Description: Naltrexone 25 or 50 mg per titration schedule
Study NCT00920829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04022343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO
Study NCT04682873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enisamium Iodide
Description: Capsule formulations of the active product (enisamium iodide 500 mg; Investigational medicinal product 1 \[IMP-1\]).~1 capsule Amizon® Max contains: enisamium iodide 500 mg.~Amizon® Max (active ingredient: enisamium iodide; IMP-1 will be administered as 1 capsule 4 times a day, every 6 hours (total dose 2,000 mg per day). Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-1 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed.
Study NCT04682873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule formulations of the reference product placebo Amizon® Max (IMP-2), will be identical in appearance (size, shape, and color), taste, and smell as the active formulation capsule.~1 capsule placebo Amizon® Max contains: placebo (no active substance).~Amizon® Max placebo (IMP-2), will be administered as 1 capsule 4 times a day every 6 hours. Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-2 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed.
Study NCT01545843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep scheduling
Description: 8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime
Study NCT01354301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: 0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml.
Study NCT03017911 — intervention group
Intervention type: PROCEDURE
Intervention: Piccline
Study NCT03494842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous nerve stimulation (TENS)
Description: The active TENS unit (delivers electrical stimulation) with indicator light
Study NCT03494842 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transcutaneous nerve stimulation (TENS)
Description: the placebo TENS unit (delivers no electrical stimulation) with indicator light
Study NCT04619745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Home and Play-Based Physical Activity Plans
Description: Play-based, parent led interventions optimized to support age appropriate physical activity, and motor skills among young children with congenital heart defects.
Study NCT03327506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Description: alprazolam 0,5 mg the eve and the morning of the surgery versus a preoperative hypnosis session
Study NCT03327506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam 0.5 mg
Description: alprazolam 0,5 mg the eve and the morning of the surgery versus a preoperative hypnosis session
Study NCT02391233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-WORTH
Description: E-WORTH (Empowering African-American Women on the Road to Health) consists of 1 Streamlined HIV Testing session followed by 5 one-and-a-half hour group sessions that will be delivered by a probation provider at the probation site. The main multimedia components used in the E-WORTH: (1) Narrativity; (2) Skill acquisition using simulated video vignettes that provides instruction and demonstration of core skills (e.g., safer sex negotiation and problem-solving skills, technical condom use skills) using culturally congruent role models; (3) Individual interactive exercises and logs that are designed to enhance participant's recall of core knowledge and tracking of their individual progress in reducing risky behaviors and achieving risk reduction goals; and a (4) Facilitator interactive guide.
Study NCT04576195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real PENS
Description: The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Frohse's~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~TENS Frequency 2 Hz TENS Pulse width - 250 microseconds Duration - 30 minutes. TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~Administration - One single session.
Study NCT04576195 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham PENS
Description: The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Frohse's~The electrical current will not be working, and the needles will be placed during 30 minutes:~- Administration - One single session
Study NCT00557505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03732010
Description: IV infusion. Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles was originally explored, yet based on emerging PK data the Cycle 1 duration is 2 weeks and then weekly. Number of Cycles: Until Progression or unacceptable toxicity develops.
Study NCT04099953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hand grip, joint range of motion , functional level of the upper extremity, physical activity levels
Description: Hand grip force with Jamar Hand Dynamometer, joint range of motion with Baseline Digital Goniometer, functional level of the upper extremity with the Shoulder-Arm and Hand Problems Questionnaire(DASH), physical activity levels with International Physical Activity Questionnaire Short Form(IPAQ-short form) and physical functions with Human Activity Profile (HAP) were evaluated.
Study NCT00652574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 70 mg by mouth twice daily x 28 days, for up to 2 years after surgery.
Study NCT03442920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This group made exercise for 12 week/3 times a week.
Study NCT01593878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TV
Description: test taken with TV on
Study NCT02181959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmaton® with DMAE
Study NCT02181959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmaton® without DMAE
Study NCT02181959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02391233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Streamlined HIV Testing
Description: In this intervention Black Women on Probation receive streamlined HIV Testing alone to test primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
Study NCT02391233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Streamlined HIV Testing
Description: In this intervention Black Women on Probation receive streamlined HIV Testing alone to test primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
Study NCT02346825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation therapy with cast
Description: Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
Study NCT02346825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation therapy with splint
Description: Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
Study NCT02346825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation bimanual
Description: Children in this group will have 3 hours of daily therapy each weekday for 4 weeks will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
Study NCT00862511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coated Total Knee Arthroplasty
Description: Implantation of a coated Total Knee Arthroplasty
Study NCT00862511 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Total Knee Arthroplasty
Description: Implantation of a Standard Total Knee Arthroplasty
Study NCT02044198 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMP2.1/AS01B
Description: 50 µg FMP2.1 in 0.5 mL of the adjuvant AS01B (containing 50 mcg MPL + 50 mcg QS21) is administered via intramuscular (IM) injection in the deltoid region of the non-dominant arm
Study NCT02271594 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Training on Best Insulin Injection Technique
Description: The intervention consists of instructing patients in whom LH is detected and who are currently injecting into it to move injections to non-LH areas; reducing insulin doses initially by 10-20% to avoid hypoglycaemia and then titrating to target control; instructing these patients to correctly rotate sites (leaving 1 cm between injection punctures and allowing used sites to heal for 2-4 weeks before injecting in them again); instructing these patients to forego needle reuse; and instructing these patients to switch to 4 mmx32G needles. A battery of tools (described below) will be used to deliver and reinforce this training, including frequent contact by phone or other electronic means after the initial training.
Study NCT02271594 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard education on injection technique
Description: Usual and customary education and training normally provided injecting patients at the center
Study NCT01080547 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery for Colorectal Cancer
Description: Laparoscopic surgery for colorectal cancer using STORZ laparoscope
Study NCT01080547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX Chemotherapy
Description: XELOX chemotherapy
Study NCT02614196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study NCT02614196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT02756858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73
Study NCT01080547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFolfox6 chemotherapy
Description: Conventional (mFolfox6) chemotherapy
Study NCT01080547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fast Track Perioperative Treatment
Description: Fast track treatment during perioperation period
Study NCT01724203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus rhamnosus
Study NCT01724203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animalis subsp. lactis
Study NCT01724203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01697137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participant Video and Provider Cueing
Description: Participants will watch a 5-minute video and then select a question about donation to discuss with their primary care provider (provider cueing).
Study NCT00311792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LapSimGyn training until expert proficiency level is reached
Description: Two consecutive simulations reaching predefined expert level
Study NCT00311792 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional clinical education
Study NCT03659487 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nissen
Description: Laparoscopic total (Nissen) fundoplication
Study NCT03659487 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toupét
Description: Laparoscopic posterior 270 degrees partial fundoplication
Study NCT03929302 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyTAP oral appliance plus mouth shield
Description: The midline traction oral appliance (MyTAP, AMI Inc., Dallas, Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared will be used in all the three arms.
Study NCT03828435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Magnetic stimulation will be given using a hand-held figure-of-eight coil with an median winding diameter of 70 mm or a cone coil (Magstim Co., Whitland, Dyfed, UK) connected to one Magstim Rapid2 Package (Magstim Co., UK). The figure-of-eight coil will be placed tangentially to the scalp with the handle pointing backwards, which is thought to preferentially activate the corticospinal cells trans-synaptically (Kaneko et al., 1996), while the cone coil will be placed along the anterioposterior axis to induce a posterior-to-anterior current in the cortex.
Study NCT01978964 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONT-10
Description: ONT-10 is a liposomal synthetic glycopolypeptide antigen formulated with PET Lipid A adjuvant
Study NCT01452035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: single session of exercise
Study NCT01080547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Perioperative Treatment
Description: Conventional treatment during perioperation period
Study NCT00412867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: 0.6 mg/kg of Alteplase is intravenously administered
Study NCT01842243 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apical pacing
Description: Pacemaker set to pace at right ventricular apex initially.
Study NCT01842243 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Septal pacing
Description: Pacemaker set to pace at right ventricular septum initially.
Study NCT01842243 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker
Description: MR conditional Pacemaker implanted in all study patients
Study NCT01960361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICE dental implant
Description: ICE- Implant Classical Esthetic implant
Study NCT04321876 — intervention group
Intervention type: BEHAVIORAL
Intervention: Collaborative Behavioral Health Program
Description: Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.
Study NCT01080547 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Surgery for Colorectal Cancer
Description: Open surgery for colorectal cancer using conventional methods